FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736730629> ?p ?o ?g. }

• W2736730629 endingPage "2439" @default.
• W2736730629 startingPage "2439" @default.
• W2736730629 abstract "Abstract The current treatment of β-thalassemia only partially mitigates the phenotype of the disease, making the need for novel therapeutic agents imperative. The investigational drug Luspatercept (ACE-536) is a ligand trap that contains the modified extracellular domain of activin receptor IIB (ACVR2B) and induces red blood cell production in an erythropoietin independent fashion. ACE-536 binds with high affinity to members of the transforming growth factor (TGF) β superfamily and therefore alters activin/GDF signaling through the intracellular SMAD complex. In search of the specific ligands, recent studies in a mouse model of β thalassemia intermedia identified growth differentiation factor 11 (GDF11) as a possible target of the drug. It has been proposed that GDF11 is overexpressed in thalassemic erythroblasts and inhibits terminal erythroid maturation via SMAD complex phosphorylation. A negative role of GDF11 in erythropoiesis has been postulated also in myelodysplastic syndrome (MDS). We recapitulate, by a genetic approach, the phenotype of thalassemic and MDS mice treated with RAP-536, the murine counterpart of ACE-536. We generated and analyzed animals with GDF11 deletion in erythroid cells (Hbbth3/+ Gdf11fl/flEpoR-Cre and NUP98-HOXD13 Gdf11fl/flEpoR-Cre) and in all hematopoietic tissues (Hbbth3/+Gdf11fl/flVav-Cre and NUP98-HOXD13 Gdf11fl/flVav-Cre). We did not detect any changes in red blood cell number, reticulocyte count, hemoglobin or hematocrit levels compared to thalassemic or MDS mice in absence of the floxed gene. Focusing on thalassemic mice, administration of RAP-536 significantly improved the anemia and other hematopoietic parameters in the peripheral blood, decreased spleen size and ameliorated ineffective erythropoiesis as indicated by an increased ratio of mature to immature splenic erythroblasts analyzed by flow cytometry. Similar endpoints were seen comparing floxed and non-floxed animals treated with RAP-536. Therefore, the lack of GDF11 in erythroid or bone marrow derived cells did not prevent a response to the drug. To assess the effect of a pancellular absence of GDF11, we are currently in process of generating a model of β-thalassemia with total Gdf11 deletion. To investigate the possible effects of RAP-536, we treated erythroid cells derived from normal or thalassemic patients with the drug. Erythroid cell viability, number, differentiation and cell cycle remained unvaried. Of note, we did not detect significant expression of GDF11/Gdf11 in human and mouse erythroid cells. To investigate the effect of an exogenous source of GDF11 production on erythroid cells, we treated murine erythroleukemia (MEL) cells with recombinant GDF11. Upon treatment we observed phosphorylation of the SMAD2/3 complex by western blot. This effect was hindered by co-treatment of GDF11 with RAP-536. We further assessed the effects of RAP-536 on the mouse erythroid transcriptome, using RNA seq analysis in splenic erythroid populations. After administration of a single dose of RAP-536, thalassemic mice were euthanized. We used flow cytometry to identify possible alterations on differentiating erythroid populations in the spleen. Notably, between 60 and 72h we observed reduced numbers of basophilic and increased numbers of polychromatophilic erythroblasts. Analysis at 60h revealed that signal transducer and activator of transcription 5a (Stat5a), cyclin-dependent kinase 6 (Cdk6) and other cell cycle-related and metabolic genes were increased in the basophilic erythroid progenitors treated with RAP-536. This effect suggests that RAP-536 promotes proliferation and/or differentiation of erythroblasts. Thus, our genetic analyses suggest that lack of GDF11 may be required but not sufficient to improve erythropoiesis. Furthermore, erythroid cells do not produce but can respond to exogenous GDF11, likely synthesized by non-erythroid cells and under conditions of ineffective erythropoiesis. Even though we detected in vitro effects, these may not mimic physiological effects, as experimental conditions may not correlate with GDF11 concentrations in vivo. As additional ligands have been proposed (such as GDF8 and Activin B), our future studies will focus on the potential role of these molecules. Altogether, these results reveal a potential alternative target of action for ACE-536 and may lead to the discovery of new therapeutic molecules. Disclosures Suragani: Acceleron Pharma: Employment, Equity Ownership. Kumar:Acceleron Pharma: Employment, Equity Ownership." @default.
• W2736730629 created "2017-07-31" @default.
• W2736730629 creator A5019803340 @default.
• W2736730629 creator A5032043830 @default.
• W2736730629 creator A5032280134 @default.
• W2736730629 creator A5045336412 @default.
• W2736730629 creator A5046499318 @default.
• W2736730629 creator A5063028370 @default.
• W2736730629 creator A5069433670 @default.
• W2736730629 creator A5075186877 @default.
• W2736730629 creator A5077816873 @default.
• W2736730629 creator A5085496842 @default.
• W2736730629 date "2016-12-02" @default.
• W2736730629 modified "2023-10-16" @default.
• W2736730629 title "Genetic Investigation of the Role of GDF11 in the Treatment of β-Thalassemia and MDS" @default.
• W2736730629 doi "https://doi.org/10.1182/blood.v128.22.2439.2439" @default.
• W2736730629 hasPublicationYear "2016" @default.
• W2736730629 type Work @default.
• W2736730629 sameAs 2736730629 @default.
• W2736730629 citedByCount "3" @default.
• W2736730629 countsByYear W27367306292017 @default.
• W2736730629 countsByYear W27367306292019 @default.
• W2736730629 crossrefType "journal-article" @default.
• W2736730629 hasAuthorship W2736730629A5019803340 @default.
• W2736730629 hasAuthorship W2736730629A5032043830 @default.
• W2736730629 hasAuthorship W2736730629A5032280134 @default.
• W2736730629 hasAuthorship W2736730629A5045336412 @default.
• W2736730629 hasAuthorship W2736730629A5046499318 @default.
• W2736730629 hasAuthorship W2736730629A5063028370 @default.
• W2736730629 hasAuthorship W2736730629A5069433670 @default.
• W2736730629 hasAuthorship W2736730629A5075186877 @default.
• W2736730629 hasAuthorship W2736730629A5077816873 @default.
• W2736730629 hasAuthorship W2736730629A5085496842 @default.
• W2736730629 hasConcept C104317684 @default.
• W2736730629 hasConcept C105580179 @default.
• W2736730629 hasConcept C109159458 @default.
• W2736730629 hasConcept C118131993 @default.
• W2736730629 hasConcept C126322002 @default.
• W2736730629 hasConcept C134018914 @default.
• W2736730629 hasConcept C153911025 @default.
• W2736730629 hasConcept C203014093 @default.
• W2736730629 hasConcept C2777799968 @default.
• W2736730629 hasConcept C2778248108 @default.
• W2736730629 hasConcept C2778403015 @default.
• W2736730629 hasConcept C2778534260 @default.
• W2736730629 hasConcept C2779703530 @default.
• W2736730629 hasConcept C2780844101 @default.
• W2736730629 hasConcept C2781080636 @default.
• W2736730629 hasConcept C28328180 @default.
• W2736730629 hasConcept C2909030593 @default.
• W2736730629 hasConcept C502942594 @default.
• W2736730629 hasConcept C54355233 @default.
• W2736730629 hasConcept C71924100 @default.
• W2736730629 hasConcept C86803240 @default.
• W2736730629 hasConcept C95444343 @default.
• W2736730629 hasConceptScore W2736730629C104317684 @default.
• W2736730629 hasConceptScore W2736730629C105580179 @default.
• W2736730629 hasConceptScore W2736730629C109159458 @default.
• W2736730629 hasConceptScore W2736730629C118131993 @default.
• W2736730629 hasConceptScore W2736730629C126322002 @default.
• W2736730629 hasConceptScore W2736730629C134018914 @default.
• W2736730629 hasConceptScore W2736730629C153911025 @default.
• W2736730629 hasConceptScore W2736730629C203014093 @default.
• W2736730629 hasConceptScore W2736730629C2777799968 @default.
• W2736730629 hasConceptScore W2736730629C2778248108 @default.
• W2736730629 hasConceptScore W2736730629C2778403015 @default.
• W2736730629 hasConceptScore W2736730629C2778534260 @default.
• W2736730629 hasConceptScore W2736730629C2779703530 @default.
• W2736730629 hasConceptScore W2736730629C2780844101 @default.
• W2736730629 hasConceptScore W2736730629C2781080636 @default.
• W2736730629 hasConceptScore W2736730629C28328180 @default.
• W2736730629 hasConceptScore W2736730629C2909030593 @default.
• W2736730629 hasConceptScore W2736730629C502942594 @default.
• W2736730629 hasConceptScore W2736730629C54355233 @default.
• W2736730629 hasConceptScore W2736730629C71924100 @default.
• W2736730629 hasConceptScore W2736730629C86803240 @default.
• W2736730629 hasConceptScore W2736730629C95444343 @default.
• W2736730629 hasIssue "22" @default.
• W2736730629 hasLocation W27367306291 @default.
• W2736730629 hasOpenAccess W2736730629 @default.
• W2736730629 hasPrimaryLocation W27367306291 @default.
• W2736730629 hasRelatedWork W1970154879 @default.
• W2736730629 hasRelatedWork W1975602859 @default.
• W2736730629 hasRelatedWork W1985854233 @default.
• W2736730629 hasRelatedWork W2004045031 @default.
• W2736730629 hasRelatedWork W2417997341 @default.
• W2736730629 hasRelatedWork W2547174614 @default.
• W2736730629 hasRelatedWork W2979511133 @default.
• W2736730629 hasRelatedWork W2980000089 @default.
• W2736730629 hasRelatedWork W2980551723 @default.
• W2736730629 hasRelatedWork W3044350043 @default.
• W2736730629 hasVolume "128" @default.
• W2736730629 isParatext "false" @default.
• W2736730629 isRetracted "false" @default.
• W2736730629 magId "2736730629" @default.
• W2736730629 workType "article" @default.